Monoclonal Antibody Therapeutics and Diagnostics For Rheumatoid Arthritis & Cancer
ModiQuest Group was founded in 2004 and is based in Nijmegen, The Netherlands. It consists of ModiQuest Therapeutics B.V, focused on the development of novel monoclonal antibody therapeutics and diagnostics for autoimmune and oncology targets, and ModiQuest Research, which provides technology and contract research for pharmaceutical and biotechnology clients.
ModiQuest’s technology centres on automated and highly efficient electrofusion technology for mouse hybridoma monoclonal antibody generation, alongside established techniques of phage display and B-cell selection for developing recombinant antibodies.
The company is currently developing novel preclinical antibody-based drug candidates and diagnostics for rheumatoid arthritis and cancer for out-licensing to diagnostic or pharmaceutical companies.